Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury
NCT ID: NCT05536076
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2023-03-01
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The proposed pilot/feasibility study will test the effect of daily acute intermittent hypercapnia (dAIHc) in individuals with SCI. The objectives of this study are to (1) determine recruitment rates and test the feasibility of recruitment, (2) calculate withdrawal and dropout rates, (3) test the feasibility and tolerability and acceptability of the proposed intervention in an SCI population, (4) develop and refine a new respiratory training intervention using dAIHc paradigm (5) derive effect size estimates for clinical endpoints and their associated variability at the end of treatment to calculate an appropriate sample size for an adequately powered clinical trial. Compared to sham therapy, the central hypothesis is that the daily respiratory muscle training (dAIHc) approach is acceptable and feasible in patients with SCI and will strengthen respiratory muscles and reduce the severity of sleep-disordered breathing (SDB), and will improve daytime symptoms.
This study is highly innovative and the first of its kind in patients with SCI, as it seeks first to use a new set of rehabilitative exercises to improve ventilation and respiratory muscles strength; secondly, it aims to use controlled randomized design; finally, it will determine the role of respiratory muscle exercises in reducing the severity of sleep symptoms and daytime function in SCI. Each aim is independently testable and does not depend on the result of the other aims. The findings will likely apply to a broad range of other neuromuscular diseases (such as Multiple Sclerosis and Stroke). The team of this pilot project has the resources and IRB approval necessary to execute the project.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention hypercapnia arm
Intermittent hypercapnia treatment five days per week for two weeks.
Hypercapnia treatment
Intermittent hypercapnia treatment five days per week for two weeks.
SCD
Intermittent hypercapnia treatment five days per week for two weeks.
Hypercapnia treatment
Intermittent hypercapnia treatment five days per week for two weeks.
Able-Bodoed
Intermittent hypercapnia treatment five days per week for two weeks.
Hypercapnia treatment
Intermittent hypercapnia treatment five days per week for two weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hypercapnia treatment
Intermittent hypercapnia treatment five days per week for two weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Spinal Injury Association (ASIA) classification A-D who have evidence of SDB (excluding those with no evidence of a neurologic deficit based on ASIA classification)
* Able-bodied patients (without SCI/D0 who have OSA.
Exclusion Criteria
* Severe congestive heart failure with ejection fraction \<35%
* Recent health event that may affect sleep
* stroke
* acute myocardial infarction
* recent surgery
* hospitalization
* Alcohol or substance abuse (\<90 days sobriety)
* Self-described as too ill to engage in study procedures
* Evidence of hypercapnia on spontaneous breathing (end-tidal CO2 \>50 mmHg)
* Unable to provide self-consent for participation
18 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Detroit Healthcare System
UNKNOWN
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdulghani Sankari, MD PhD
Role: PRINCIPAL_INVESTIGATOR
John D. Dingell VA Medical Center, Detroit, MI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
John D. Dingell VA Medical Center, Detroit, MI
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Abdulghani Sankari, MD PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B4114-P
Identifier Type: -
Identifier Source: org_study_id